Galaxy Medicare
Galaxy Medicare Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Top 10 Healthcare Equipment & Supplies companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Galaxy Medicare's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
- Revenue from Operations (₹ Mn): - FY23: 312 - FY24: 362 (16% increase YoY) - FY25: 392 (8.3% increase YoY) - FY26: 400 (2% increase YoY) - Export sales grew from ₹73 Mn in FY23 to ₹98 Mn in FY26.
From Galaxy Medicare's Q2 FY27 earnings-call transcript · updated 24 Oct 2026.
Revenue & Sales Performance
- Revenue from Operations (₹ Mn):
- FY23: 312
- FY24: 362 (16% increase YoY)
- FY25: 392 (8.3% increase YoY)
- FY26: 400 (2% increase YoY)
- Export sales grew from ₹73 Mn in FY23 to ₹98 Mn in FY26.
- Domestic revenue for FY26 was ₹302 Mn with strong regional sales in Maharashtra (30%) and Gujarat (23%).
2 more points from Galaxy Medicare's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Galaxy Medicare said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company plans to deploy IPO capex for new machinery, including a pre-cotton cleaning line, aimed at lifting throughput and reducing input cost. (Page 23)
- Capex is currently underway for a new pre-cotton cleaning line to add backward integration and increase throughput. (Page 16)
- Installed capacity shows some core lines near or above 100% utilization (POP Bandage 106%, Elastic Adhesive Bandage 91%) indicating the need for capacity enhancement. (Page 16)
- The focus is on enhancing capacity & backward integration through machinery upgrades rather than new plant construction. (Page 23)
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Galaxy Medicare said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Continue your research
Others in Healthcare Equipment & Supplies this season
- Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Q-Line BiotechGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Galaxy Medicare and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Galaxy Medicare Q2 FY27 results?
- Revenue from Operations (₹ Mn): - FY23: 312 - FY24: 362 (16% increase YoY) - FY25: 392 (8.3% increase YoY) - FY26: 400 (2% increase YoY) - Export sales grew from ₹73 Mn in FY23 to ₹98 Mn in FY26.
What is Galaxy Medicare share price analysis?
Galaxy Medicare currently shows a neutral. The stock trades at a P/E of 7.9 with a market cap of ₹27 Cr. Investors should review the full earnings analysis for detailed insights.
Is Galaxy Medicare planning capital expenditure?
The company plans to deploy IPO capex for new machinery, including a pre-cotton cleaning line, aimed at lifting throughput and reducing input cost.
Keep Galaxy Medicare on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.